Search
Fingolimod
go.drugbank.com/drugs/DB08868ApprovedInvestigationalIt was developed by Novartis and initially approved by the FDA in 2010.[L12651] Fingolimod was also studied for the treatment of COVID-19, the disease caused by infection with the SARS-CoV-2 virus. … [A176474] Fingolimod is a sphingosine 1-phosphate receptor modulator for the treatment of relapsing-remitting multiple sclerosis.
Categories: Experimental Unapproved Treatments for COVID-19Tepotinib
go.drugbank.com/drugs/DB15133ApprovedInvestigationalTepotinib was first approved in Japan in March 2020 for the treatment of non-small cell lung cancers (NSCLC) with _MET_ alterations, and was subsequently granted accelerated approval by the US FDA in February … In February 2022, tepotinib was approved for use in Europe.[L42200]
Brincidofovir
go.drugbank.com/drugs/DB12151ApprovedInvestigationalCidofovir itself has broad antiviral activity against several DNA viruses,[A235725] resulting in brincidofovir being investigated for the prevention and treatment of cytomegalovirus (CMV), BK Virus (BKV … The approval was granted under the agency’s Animal Rule,[L34480] which allows for a drug to be approved based on the results of well-controlled animal studies when human trials would be unethical or infeasible
Categories: Antivirals for Systemic Use, Antiinfectives for Systemic UseISS-1018
go.drugbank.com/drugs/DB05463InvestigationalIt is also being investigated in combination with rituximab for treatment of b-cell or non-hodgkin's lymphoma. … ISS 1018 is currently being investigated in combination with HBsAg vaccine as a prophylactic treatment for to prevent Hepatitis B in adults.
Brepocitinib
go.drugbank.com/drugs/DB15003ApprovedInvestigational[L64097] The FDA approved brepocitinib on August 27, 2026 for the treatment of dermatomyositis in adult patients, making it the first targeted oral therapy approved for the condition.[L64115] … [L64097] Brepocitinib is not recommended in combination with other JAK inhibitors, other TYK2 inhibitors, or biologic DMARDs.
Marnetegragene autotemcel
go.drugbank.com/drugs/DB17595Approved[L56115, L56116] Marnetegragene autotemcel is indicated for pediatric patients with severe LAD-I lacking an available HLA-matched sibling donor.[L56115] … Severe leukocyte adhesion deficiency-I (LAD-I) is a genetic disorder leading to frequent life-threatening infections and high fatality risks among affected pediatric patients.
Synonyms: Autologous CD34+ cells transduced ex vivo with a lentiviral vector (Chim-CD18-WPRE) encoding the ITGB2 geneCorynebacterium diphtheriae
go.drugbank.com/drugs/DB09877ApprovedInvestigationalThe vaccine is intramuscularly administered to provide active immunization against diphtheria in infants and children. … The bacteria culture is grown in a medium and through purification, diphtheria toxin is detoxified with formaldehyde and diafiltered.
Mixtures: PREVENAR 13 SUSPENSION FOR INJECTION, Boostrix Injektionssuspension in einer FertigspritzeBaxdrostat
go.drugbank.com/drugs/DB19090ApprovedInvestigationalOn May 18, 2026, baxdrostat was approved by the FDA as a first-in-class aldosterone synthase inhibitor for the treatment of hypertension in combination with other antihypertensive drugs [L56189]. … Baxdrostat is an orally bioavailable, highly selective, first-in-class small-molecule aldosterone synthase inhibitor (ASI) designed to block the production of aldosterone [A275512].
Synonyms: (+)-(r)-n-(4-(1-methyl-2-oxo-1,2,3,4-tetrahydroquinolin-6-yl)-5,6,7,8-tetrahydroisoquinolin-8-yl)propionamide, N-((8r)-5,6,7,8-tetrahydro-4-(1,2,3,4-tetrahydro-1-methyl-2-oxo-6-quinolinyl)-8-isoquinolinyl)propanamideGimeracil
go.drugbank.com/drugs/DB09257ApprovedInvestigationalfor continued cancer growth. … Gimeracil's main role within Teysuno is to prevent the breakdown of [DB00544] (5-FU), which helps to maintin high enough concentrations for sustained effect against cancer cells [L933].
Synonyms: Ts-1 (TN)Piflufolastat F 18
go.drugbank.com/drugs/DB14805ApprovedInvestigationalIt was first approved by the FDA in May 2021 under the brand name Pylarify and aims to allow for earlier and more accurate detection of suspected prostate cancer metastases or recurrences. … [L34324] On July 28, 2023, the EMA also approved Piflufolastat F18 under the brand name PYLCLARI for primary staging or localizing recurrence of prostate cancer.[L47586]